IJCM  Vol.5 No.14 , July 2014
PPPM (Predictive, Preventive and Personalized Medicine) as a New Model of the National and International Healthcare Services and Thus a Promising Strategy to Prevent a Disease: From Basics to Practice
ABSTRACT

Nowadays the system of public health is constructed in such a manner so that its main objective is the recovery of an already sick person, while prediction and prevention receive little attention. Meanwhile the development of these aspects of medicine can lead to the ability to control morbidity among the population, to identify chronic and genetic diseases in the early stages of development, and thus to prevent their further progression. This will reduce traditionally high costs of sick people treatment and the number of disabled population, and improve the quality and duration of life. The elaboration of new fields of science that are working on the study and interpretation of data obtained during laboratory and clinical research, creation of new methods for diagnosis, prognosis and treatment, provides an opportunity now to implement a new strategy, called PPPM, and gets promising results, which should lead to further development of an existing medicine.


Cite this paper
Sadkovsky, I. , Golubnitschaja, O. , Mandrik, M. , Studneva, M. , Abe, H. , Schroeder, H. , Antonova, E. , Betsou, F. , Bodrova, T. , Payne, K. and Suchkov, S. (2014) PPPM (Predictive, Preventive and Personalized Medicine) as a New Model of the National and International Healthcare Services and Thus a Promising Strategy to Prevent a Disease: From Basics to Practice. International Journal of Clinical Medicine, 5, 855-870. doi: 10.4236/ijcm.2014.514115.
References
[1]   Ray, R. (2012) The Future of Medicine. American Journal of Medicine, 125, 236-239.
http://www.ncbi.nlm.nih.gov/pubmed/22340917
http://dx.doi.org/10.1016/j.amjmed.2011.06.035


[2]   Gabibov, A.G., Paltsev, M.A. and Suchkov, S.V. (2011) Antibody-Associated Proteolysis in Surveillance of Autoimmune Demyelination: Clinical and Preclinical Issues. Future Neurology, 6, 303-305.
http://www.futuremedicine.com/toc/fnl/6/3
http://dx.doi.org/10.2217/fnl.11.17


[3]   Bodrova, T.A., Kostyushev, D.S., Antonova, E.N., Slavin, S., Gnatenko, D.A., Bocharova, M.O., Legg, M., Pozzilli, P., Paltsev, M.A. and Suchkov, S.V. (2012) Introduction into PPPM as a New Paradigm of Public Health Service: An Integrative View. EPMA Journal, 3, 16.
http://www.epmajournal.com/content/3/1/16

[4]   Golubnitschaja, O. and Costigliola, V. (2010) Common Origin but Individual Outcomes: Time for New Guidelines in Personalised Healthcare. Personalized Medicine, 7, 561-568.
http://www.futuremedicine.com/doi/abs/10.2217/pme.10.42
http://dx.doi.org/10.2217/pme.10.42


[5]   Nair, V.S., Maeda, L.S. and Ioannidis, J.P. (2012) Clinical Outcome Prediction by microRNAs in Human Cancer: A Systematic Review. Journal of the National Cancer Institute, 104, 528-540.
http://jnci.oxfordjournals.org/content/early/2012/03/06/jnci.djs027.full
http://dx.doi.org/10.1093/jnci/djs027


[6]   Jones, T. and Price, P. (2012) Development and Experimental Medicine Applications of PET in Oncology: A Historical Perspective. Lancet Oncology, 13, e116-e125.
http://www.ncbi.nlm.nih.gov/pubmed/22381934
http://dx.doi.org/10.1016/S1470-2045(11)70183-8


[7]   Patel, N.R., McPhail, M.J., Shariff, M.I., Keun, H.C. and Taylor-Robinson, S.D. (2012) Biofluid Metabonomics Using (1)H NMR Spectroscopy: The Road to Biomarker Discovery in Gastroenterology and Hepatology. Expert Review of Gastroenterology and Hepatology, 6, 239-251.
http://www.ncbi.nlm.nih.gov/pubmed/22375528
http://dx.doi.org/10.1586/egh.12.1


[8]   Hood, L., Balling, R. and Auffray, C. (2012) Revolutionizing Medicine in the 21st Century through Systems Approaches. Biotechnology Journal, 7, 992-1001.
http://www.ncbi.nlm.nih.gov/pubmed/22815171
http://dx.doi.org/10.1002/biot.201100306


[9]   Tran, B., Dancey, J.E., Kamel-Reid, S., McPherson, J.D., Bedard, P.L., Brown, A.M., Zhang, T., Shaw, P., Onetto, N., Stein, L., Hudson, T.J., Neel, B.G. and Siu, L.L. (2012) Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 30, 647-660.
http://www.ncbi.nlm.nih.gov/pubmed/22271477
http://dx.doi.org/10.1200/JCO.2011.39.2316


[10]   Scott, S.A. (2011) Personalizing Medicine with Clinical Pharmacogenetics. Genetics in Medicine, 13, 987-995.
http://www.ncbi.nlm.nih.gov/pubmed/22095251
http://dx.doi.org/10.1097/GIM.0b013e318238b38c


[11]   Saubermann, A.J. and Lagasse, R.S. (2012) Prediction of Rate and Severity of Adverse Perioperative Outcomes: “Normal Accidents” Revisited. Mount Sinai Journal of Medicine, 79, 46-55.
http://www.ncbi.nlm.nih.gov/pubmed/22238038
http://dx.doi.org/10.1002/msj.21295


[12]   Lemke, H.U. and Berliner, L. (2011) Patient Specific Modeling and Model Guided Therapy. EPMA Journal, 2, 181-182.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405420/

[13]   Farra, N., Manickaraj, A.K., Ellis, J. and Mital, S. (2012) Personalized Medicine in the Genomics Era: Highlights from an International Symposium on Childhood Heart Disease. Future Cardiology, 8, 157-160.
http://www.ncbi.nlm.nih.gov/pubmed/22413975
http://dx.doi.org/10.2217/fca.12.3


[14]   Kostyushev, D., Tsarev, I., Gnatenko, D., Paltsev, M. and Suchkov, S. (2011) Myelin-Associated Serological Targets as Applicable to Diagnostic Tools to Be Used at the Preclinical and Transient Stages of Multiple Sclerosis Progression. Open Journal of Immunology, 1, 80-86.
http://www.scirp.org/journal/PaperInformation.aspx?paperID=16662#.U3_Xavnud8E

[15]   Jain, K.K. (2012) Role of Nanodiagnostics in Personalized Cancer Therapy. Clinics in Laboratory Medicine, 12, 15-31.
http://www.ncbi.nlm.nih.gov/pubmed/22340841
http://dx.doi.org/10.1016/j.cll.2011.10.001


[16]   Khitrov, A.N., Shogenov, Z.S., Tretyak, E.B., Ischenko, A.I., Matsuura, E., Neuhaus, O., Paltsev, M.A. and Suchkov, S.V. (2007) Postinfectious Immunodeficiency and Autoimmunity: Pathogenic and Clinical Values and Implications. Expert Review of Clinical Immunology, 3, 323-331.
http://www.ncbi.nlm.nih.gov/pubmed/20477676
http://dx.doi.org/10.1586/1744666X.3.3.323


[17]   Robinton, D.A. and Daley, G.Q. (2012) The Promise of Induced Pluripotent Stem Cells in Research and Therapy. Nature, 481, 295-305.
http://www.ncbi.nlm.nih.gov/pubmed/22258608
http://dx.doi.org/10.1038/nature10761


[18]   Sheiman, I. and Shishkin, S. (2010) New Challenges and New Objectives Problems of Economic Transition. Russian Health Care, 52, 4-49.
http://connection.ebscohost.com/c/articles/49240513/russian-health-care-new-challenges-new-objectives

 
 
Top